Invuity (IVTY) Receives a Buy from Northland Securities

Northland Securities analyst Suraj Kalia maintained a Buy rating on Invuity (NASDAQ: IVTY) yesterday and set a price target of $6. The company’s shares opened today at $7.35.

According to, Kalia is a 5-star analyst with an average return of 16.1% and a 62.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Apollo Endosurgery Inc, and Edwards Lifesciences.

Invuity has an analyst consensus of Hold, with a price target consensus of $7.05.

See today’s analyst top recommended stocks >>

Based on Invuity’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $8.95 million. In comparison, last year the company had a GAAP net loss of $10.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Invuity, Inc. is a medical technology company, which engages in the development and marketing of surgical and medical devices. Its products include retractors, handhelds, and drop-ins under the Photonics and PhotonBlade brands. The company was founded by Kenneth B. Trauner and Alex Vayser on November 29, 2004 and is headquartered in San Francisco, CA.